An interprofessional team provides an integrated approach for treatment decisions in NET to achieve the best clinical outcomes. Given the newness of this agent, all clinicians, specialists, nurses, and pharmacists (particularly nuclear medicine specialty pharmacists) on the case need to remain updated on the latest clinical trials and share their findings with the rest of the team so that everyone has the latest clinical data from which to operate.

Therapies such as Lu 177 hold promise in treating this otherwise doleful clinical situation. Where possible, patients should be encouraged to enter clinical trials. Their service benefits future patients.